Advancements in Lynch Syndrome Vaccines: A New Hope for Cancer Prevention

A Personal Journey with Lynch Syndrome

Dr. Stacy Norton’s experience with cancer began early. Her mother passed away from colon cancer when Norton was just 7, a tragedy shared by several family members struck by aggressive tumors at young ages. Now, Norton takes part in research aimed at discovering if new vaccines can protect her children and herself from similar fates.

As a Houston doctor, Norton is among roughly 1 million Americans afflicted by Lynch syndrome. This inherited genetic fault significantly increases risks for colorectal cancer and heightens vulnerability to other types of cancers. Those affected often undergo frequent colonoscopies, annually monitoring for and removing precancerous growths or polyps.

Innovative Vaccine Research

Scientists are now exploring vaccines that aim to further bolster defenses, teaching the immune system to preemptively intercept potential colon cancers before they fully develop. Currently, three Lynch syndrome vaccines are under development, with two in early clinical trials in the U.S. and another starting in Britain.

The vaccine Norton tested shows enough promise that a leading researcher, Dr. Eduardo Vilar-Sanchez from MD Anderson Cancer Center, anticipates a larger study in the coming year. Norton, 59, who successfully overcame her Lynch-induced cancer and has two children in their 20s with the inherited mutation, is optimistic. If successful, these vaccines might alleviate the need for annual colonoscopies for her children.

The Genetic Root of Lynch Syndrome

Lynch syndrome originates from an inherited genetic mutation affecting what are known as mismatch-repair genes. These genes serve as cellular spellcheckers, correcting DNA errors during cell multiplication. However, a faulty gene within this system impairs the body’s ability to manage these errors, escalating the development of tumors, typically before age 50.

While the average person’s lifetime risk for colorectal cancer stands at 5%, Lynch syndrome carriers face risks as high as 80%, depending on the specific gene affected. Other cancers associated with Lynch include endometrial, pancreatic, stomach, ovarian, skin cancers, and certain brain tumors.

Vaccine Development for Genetic Cancer Prevention

Unlike existing vaccines for virus-related cancers, creating vaccines for gene-induced cancers presents unique challenges. Lynch syndrome-related tumors tend to accumulate numerous mutations, creating novel proteins not seen in healthy cells.

In an initial study, Norton and 44 other individuals with Lynch syndrome tested a Swiss biotech Nouscom vaccine aiming to encourage immune recognition of 209 abnormalities found in Lynch-related precancers. Results showed increased tumor-eliminating T cells, fewer precancerous growths, and absence of advanced polyps as reported by the MD Anderson team in Nature Medicine.

Dr. John Marshall, an oncologist at Georgetown University, noted this early research as potentially significant in stimulating the immune system to combat Lynch syndrome-driven tumor developments.

Norton witnessed promising results in her personal health, with colonoscopies one and two years post-vaccination showing no polyps for the first time since 2014. She is part of a subgroup receiving booster shots, and further information is anticipated soon.

Further Vaccine Trials and Considerations

Oxford University researchers are testing a Moderna-generated mRNA vaccine, harnessing technology akin to its COVID-19 vaccine, targeting Lynch-based precancers. Concurrently, scientists await outcomes from trials comparing ImmunityBio’s Tri-Ad5 vaccine against a placebo. This vaccine highlights different cancer markers.

Lynch syndrome may partially explain increasing colon cancer diagnoses in younger adults, although other factors might contribute. As genetic testing becomes more prevalent, more individuals may learn of their Lynch syndrome risk, prompting earlier screenings and preventative measures like colonoscopies.

For the general population, routine colorectal cancer screenings start at age 45. Anyone experiencing symptoms like blood in stool or rectal bleeding, unusual bowel habit changes, unexplained weight loss, or abdominal pain should seek medical evaluation.